Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. - Budde LE; Kamdar M; Assouline SE; Chavez JC; Ghosh N; Ollila TA; Hodson DJ; Modi D; Bastos-Oreiro M; Naik SG; Nakhoda SK; Batlevi CL MD, PhD; et al. (Blood, 2026)